Journals / İstanbul Kuzey Klinikleri / 2020 / Cilt: 7 - Sayı: 3

Economic analysis of oral posaconazole prophylaxis in acute myeloid leukemia during remission induction in Turkey

Pages
222–225
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In patients on PAT, the mean numberof transfused platelet units was six (0–9), while 12.51 (4–43) units for patients who were not on PAT.CONCLUSION: In our study, the oral suspension form of posaconazole was observed to be cost-effective to prevent IFI witha significant decrease in mortality during remission induction treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Invasive fungal infections (IFI) are important and trending causes of mortality in patients with acute leukemia,especially during the remission induction.METHODS: In this study, 225 patients who were diagnosed with acute myeloid leukemia (AML) and undergoing intensivetreatment for remission induction were enrolled in a retrospective manner.RESULTS: Within the whole group, which consisted of 225 patients, 90 patients received prophylactic antifungal treatment(PAT) (40%), while 135 patients did not (60%) receive.
📊
Key Findings & Data:The mean cost of hospitalization was 9.151,6 (2.872,6–20.483,3)US dollars.
💡
Conclusion & Impact:In patients on PAT, the mean numberof transfused platelet units was six (0–9), while 12.51 (4–43) units for patients who were not on PAT.CONCLUSION: In our study, the oral suspension form of posaconazole was observed to be cost-effective to prevent IFI witha significant decrease in mortality during remission induction treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Invasive fungal infections (IFI) are important and trending causes of mortality in patients with acute leukemia,especially during the remission induction.METHODS: In this study, 225 patients who were diagnosed with acute myeloid leukemia (AML) and undergoing intensivetreatment for remission induction were enrolled in a retrospective manner.RESULTS: Within the whole group, which consisted of 225 patients, 90 patients received prophylactic antifungal treatment(PAT) (40%), while 135 patients did not (60%) receive. The mean cost of hospitalization was 9.151,6 (2.872,6–20.483,3)US dollars. Gender distribution and mean ages of groups were similar. One hundred fourteen patients not on PAT (84.4%)and five patients on PAT (5.5%) received intravenous antifungal treatment. Thirty-two of the patients who were not on PAT(23.7%) and 11 of the patients on PAT died during remission induction (12.22%). The mean day of the hospitalization was22.61 days for the patients on PAT and 33.89 days for the patients who were not on PAT. In patients on PAT, the mean numberof transfused platelet units was six (0–9), while 12.51 (4–43) units for patients who were not on PAT.CONCLUSION: In our study, the oral suspension form of posaconazole was observed to be cost-effective to prevent IFI witha significant decrease in mortality during remission induction treatment.

🔖

Cite This Article

KIRKIZLAR, H. O., DEMİR, A. M., BAYSAL, M., ÜMİT, E. G. (2022). Economic analysis of oral posaconazole prophylaxis in acute myeloid leukemia during remission induction in Turkey. İstanbul Kuzey Klinikleri, Cilt: 7 - Sayı: 3, 222–225. https://ajindex.com/articles/551391

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Zhang R, Chen J, Huang H, Ma J, Meng F, Tang Y, et al. Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study. Int J Hematol 2017;106:221–8
  2. Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol 2018;97:197–207
  3. Berking S, Doedens D, Horns H, Fiegl M, Ostermann H, Rieger CT. Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting. Mycoses 2017;60:600–6
  4. Wang ES. Guideline recommendations for the prophylaxis of invasive aspergillosis in AML. Clin Adv Hematol Oncol 2016;14:876–9
  5. Hachem R, Assaf A, Numan Y, Shah P, Jiang Y, Chaftari AM, et al. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. Int J Antimicrob Agents 2017;50:384–8
  6. Busca A, Lessi F, Verga L, Candoni A, Cattaneo C, Cesaro S, et al; on the behalf of the SEIFEM Group (Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne). SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy. Leuk Lymphoma 2017;58:2859–64
  7. Cámara R, Gozalbo I, Jurado M, Sanz J, Aragón B, Grau S. Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. Adv Ther 2017;34:2104–19
  8. Sung AH, Marcella SW, Xie Y. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States. J Med Econ 2015;18:341–8.